efavirenz and HIV
efavirenz has been researched along with HIV in 112 studies
Research
Studies (112)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (3.57) | 18.2507 |
| 2000's | 41 (36.61) | 29.6817 |
| 2010's | 54 (48.21) | 24.3611 |
| 2020's | 13 (11.61) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P | 1 |
| Anand, B; Bal, TR; Sriram, D; Yogeeswari, P | 1 |
| Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M | 1 |
| Allan, G; Barba, O; Burt, C; Corbau, R; Dupont, T; Irving, S; Jones, LH; Knöchel, T; Middleton, DS; Mowbray, CE; Perros, M; Phillips, C; Ringrose, H; Swain, NA; Webster, R; Westby, M | 1 |
| Boland, S; Cauvin, C; de Walque, S; Demonté, D; Durant, F; Georges, B; Hevesi, L; Le Van, K; Martinelli, V; Van Lint, C | 1 |
| Andries, K; Benjahad, A; de Béthune, MP; Decrane, L; Grierson, DS; Guillemont, J; Hertogs, K; Nguyen, CH; Oumouch, S; Palandjian, P; Queguiner, L; Vernier, D | 1 |
| Botta, M; Brai, A; Canducci, F; Ceresola, ER; Clementi, M; Corona, A; Esposito, F; Grandi, N; Tintori, C; Tramontano, E | 1 |
| Ashok, P; Chander, S; Murugesan, S; Wang, P; Yang, LM; Zheng, YT | 1 |
| Elgaher, WA; Hartmann, RW; Haupenthal, J; Mély, Y; Pires, M; Real, E; Saladini, F; Sharma, KK | 1 |
| Chen, FE; Gu, SX; Liu, GY; Meng, G; Pannecouque, C; Tang, JF; Wu, FS; Xiao, T; Xu, ZQ; Zhu, YY | 1 |
| De Clercq, E; Gao, P; Liu, X; Pannecouque, C; Song, S; Sun, L; Wang, Z; Zhan, P; Zhang, J | 1 |
| Adankie, BT; Aklillu, E; Amogne, W; Engidawork, E; Shibeshi, W; Tadesse, WT | 1 |
| Aarnoutse, R; Aber, F; Alinaitwe, L; Buzibye, A; Denti, P; Dooley, KE; Gausi, K; Kengo, A; Lamorde, M; Musaazi, J; Nabisere, R; Najjemba, L; Nampala, J; Omali, D; Otaalo, B; Sekaggya-Wiltshire, C; Sloan, DJ | 1 |
| Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z | 1 |
| Adimora, AA; Althoff, KN; Cole, SR; Edwards, JK; Eron, JJ; Gebo, K; Gill, MJ; Horberg, MA; Hudgens, MG; Jetsupphasuk, M; Kitahata, MM; Lang, R; Lima, VD; Lu, H; Marconi, VC; Moore, RD; Rabkin, C; Rebeiro, PF; Silverberg, MJ; Sterling, TR | 1 |
| Mendicino, CCP; Pádua, CAM; Silva, GJD; Tupinambás, U | 1 |
| Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H | 1 |
| Amara, A; Byakika-Kibwika, P; Byamugisha, J; Coombs, JA; Else, L; Gini, J; Heiburg, C; Hill, A; Hodel, EM; Kaboggoza, J; Khoo, S; Kintu, K; Lamorde, M; Malaba, T; Mehta, U; Myer, L; Orrell, C; Reynolds, H; Sihlangu, M; Simmons, B; Singh, Y; Waitt, C; Walimbwa, S | 1 |
| George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ | 1 |
| Bhattacharya, D; Chaktoura, N; Chipato, T; Currier, JS; Dula, D; Fowler, MG; George, K; Gnanashanmugam, D; Gupta, A; Huang, S; Klingman, KL; Martinson, F; Mohtashemi, N; Peters, MG; Tierney, C | 1 |
| Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z | 1 |
| Eriksson, LE; Marrone, G; Mellgren, Å; Reinius, M; Svedhem, V | 1 |
| Bengtson, AM; Cole, SR; Collier, AC; Crane, HM; Eaton, EF; Edwards, JK; Mathews, WC; Mollan, KR; O'Cleirigh, C; Pence, BW; Tierney, C; Weideman, AMK; Westreich, D; Xu, S | 1 |
| Aniceto, N; Antunes, F; Cruz, JP; Duarte, H; Fernandes, A; Morais, J; Paixão, P; Ribeiro, AC | 1 |
| Dahl, ML; Eriksen, J; Gustafsson, LL; Navér, L; Österberg, E; Rubin, J; Soeria-Atmadja, S | 1 |
| Jordaan, MA; Shapi, M | 1 |
| de Mast, Q; Kinabo, GD; Mchaile, DN; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Mbete, N; Murnane, PM; Patel, F; Shiau, S; Strehlau, R | 1 |
| Chen, X; Fairley, CK; He, J; Jing, J; Mao, L; Sasadeusz, J; Su, S; Wei, X; Zeng, H; Zhang, L | 1 |
| Aweeka, FT; Jagannathan, P; Kajubi, R | 1 |
| Srinivas, NR | 1 |
| Johnston, J; Joubert, A; Orrell, C; Smith, P; Wiesner, L | 1 |
| Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS | 1 |
| Bangsberg, DR; Boum, Y; Bwana, B; Chang, JL; Haberer, JE; Hunt, PW; Kroetz, DL; Lee, SA; Martin, J; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC | 1 |
| Tartaglia, A | 1 |
| Avenant, T; du Plessis, N; George, J; Goga, AE; Mazanderani, AH; Murray, TY; Pepper, MS; Sherman, GG; Snyman, T | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Sukasem, C; Sungkanuparph, S | 1 |
| Cabrera Figueroa, S; Carracedo Álvarez, A; Cruz Guerrero, R; Hurlé, AD; Hurtado, LP; Sánchez Martín, A | 1 |
| Heger, M | 1 |
| Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB | 1 |
| Calvo Hernández, MV; Figueroa, SC; García-Berrocal, B; Gómez, AI; Gonzalez-Buitrago, JM; Isidoro-García, M; Martín, AF; Martín, AS; Sánchez, MC; Tovar, CB; Valverde Merino, MP | 1 |
| Berhanu, R; Brennan, AT; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Amin, J; Back, D; Boffito, M; Carey, D; Clarke, A; Cooper, DA; Dickinson, L; Egan, D; Else, L; Emery, S; Khoo, S; Losso, M; Orrell, C; Owen, A; Phanuphak, P; Puls, R | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Dickinson, L; Owen, A; Siccardi, M | 1 |
| Bangsberg, D; Bienczak, A; Cohen, K; Denti, P; Maartens, G; Orrell, C; Wood, R | 1 |
| Belyhun, Y; Liebert, UG; Maier, M | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG | 1 |
| Hallenberger, S; Jochmans, D; Lavens, D; Lemmens, I; Lievens, S; Pattyn, E; Tavernier, J; Van der Heyden, J; Verhee, A | 1 |
| Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S | 1 |
| Avalos, A; Essex, M; Gaolathe, T; Hughes, MD; Mboya, JJ; Moffat, HJ; Ndwapi, N; Shapiro, RL; Shipton, LK; Stock, S; Thior, I; Wester, CW; Widenfelt, E | 1 |
| Burrell, CJ; Carr, JM; Daly, L; Green, T; Hart, W; Higgins, G; Li, P; Qiao, M; Ratcliff, R; Shaw, D | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Avihingsanon, A; Belloso, WH; Boesecke, C; Cooper, DA; Duncombe, C; Emery, S; Gazzard, B; Li, L; Molina, JM; Petoumenos, K; Puls, RL; Srasuebkul, P | 1 |
| Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Giuliano, M; Marazzi, MC; Nielsen-Saines, K; Palombi, L | 1 |
| Boima, V; Flanigan, TP; Kenu, E; Kwara, A; Lartey, M; Mingle, JA; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Seshie, M; Wu, H; Xexemeku, F; Yang, H | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H | 1 |
| Chiappetta, DA; de Celis, ER; Facorro, G; Sosnik, A | 1 |
| DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Luque, AE; Ma, Q; Morse, GD; Venuto, CS; Zingman, BS | 1 |
| Abrams, EJ; Coovadia, A; Dandara, C; Kuhn, L; Maisel, J; Martens, L; Norman, J; Strehlau, R | 1 |
| Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A | 1 |
| Kuhn, L; Meyers, TM; Moultrie, H; Yotebieng, M | 1 |
| Aleixo, AW; Arruda, MB; de M Brindeiro, R; Greco, DB; Martins, AN; Pires, AF; Tanuri, A | 1 |
| Durant, J; Duvivier, C; Fätkenheuer, G; Hill, A; Marks, S; Rey, D; Rieger, A; Schmidt, W; van Delft, Y | 1 |
| Back, D; Dickinson, L; Watson, V; Yilmaz, A | 1 |
| Krogstad, PA; Marsden, MD; Zack, JA | 1 |
| Back, D; Battegay, M; de Roche, M; Livio, F; Marzolini, C; Siccardi, M; Stoeckle, M | 1 |
| Lefebvre, J; Levin, P; Perkins, TJ | 1 |
| Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S | 1 |
| Biasin, M; Clerici, M; Di Pietro, M; Lo Caputo, S; Maserati, R; Mazzotta, F; Ravasi, G; Seminari, E; Trabattoni, D | 1 |
| Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M | 1 |
| Desta, Z; Flockhart, DA; Gorski, JC; Hall, SD; Jones, DR; Ward, BA | 1 |
| Bowonwatanuwong, C; Chantratita, W; Chetchotisakd, P; Mootsikapun, P; Sungkanuparph, S; Tansuphaswaswadikul, S; Vibhagool, A | 1 |
| Bouvet, E; Descamps, D; Larouzé, B; Massari, V; Parienti, JJ; Vabret, A; Verdon, R | 1 |
| Bordenave, B; Claxton, S; Henry, K; Kane, E; Klebert, M; Powderly, WG; Tebas, P; Yarasheski, K | 1 |
| Boeri, E; Castagna, A; Gallotta, G; Gianotti, N; Maillard, M; Ratti, D; Serra, G; Tremolada, Y; Vacchini, D | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Beerenwinkel, N; Drton, M | 1 |
| Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR | 1 |
| Breilh, D; Camou, F; Caubet, O; Djabarouti, S; Fleury, H; Lavit, M; Pellegrin, I; Pellegrin, JL; Saux, MC | 1 |
| de Campos, AV; Leon, E; Lopez-Cortes, LF; Lozano, F; Marin-Niebla, A; Marquez-Solero, M; Ruiz-Morales, J; Ruiz-Valderas, R; Valiente, R | 1 |
| Aubertin, AM; Burrer, R; Einius-Haessig, S; Moog, C; Pancino, G; Richert, S; Salmon-Ceron, D; Spiridon, G | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Cecelia, AJ; Devaleenal, B; Flanigan, T; Kumarasamy, N; Mayer, KH; Muthu, S; Palanivel, V; Venkatesh, KK; Yepthomi, T | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Cordova, B; Jackson, DA; Rayner, MM | 1 |
| Collier, AC; Schwartz, MA | 1 |
| Chen, CY; Tan, L | 1 |
| Duval, X | 1 |
| Belec, L; Castiel, P; Clavel, F; Gonzalez-Canali, G; Kazatchkine, MD; Peytavin, G; Piketty, C; Race, E; Si-Mohamed, A; Weiss, L | 1 |
| Baird, BF; Chun, TW; Dybul, M; Engel, D; Fauci, AS; Fox, CH; Green, LG; Hertogs, K; Larder, B; Li, Y; Liu, S; Mican, JM; Orenstein, JM; Ward, DJ | 1 |
| Barry, M; Clarke, S; Harrington, P; Mulcahy, F | 1 |
Reviews
5 review(s) available for efavirenz and HIV
| Article | Year |
|---|---|
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Genome, Viral; HIV; HIV Infections; Humans; Interdisciplinary Communication; Models, Molecular; Molecular Structure; Mutation; Nitriles; Pyrimidines; Rilpivirine | 2005 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
[Maraviroc efficacy in clinical studies on the development of the molecule].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2008 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Strategies for second-line antiretroviral therapy in adults with HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Virus Latency; Virus Replication | 1999 |
Trials
25 trial(s) available for efavirenz and HIV
| Article | Year |
|---|---|
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Topics: Anti-HIV Agents; Benzoxazines; HIV; HIV Infections; Humans; Rifampin; Tuberculosis | 2023 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 2023 |
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Milk, Human; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Assessment; South Africa; Treatment Outcome; Uganda; Viral Load; Young Adult | 2019 |
Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.
Topics: Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV; HIV Infections; Humans; Infant; Pregnancy | 2021 |
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
Topics: Adult; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; Genomics; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Neurotransmitter Transport Proteins; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Neurotransmitter; Reverse Transcriptase Inhibitors | 2018 |
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Female; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2015 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2010 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.
Topics: Alkynes; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Monitoring; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; RNA, Viral; Substance-Related Disorders | 2011 |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Prospective Studies; Treatment Outcome; Viral Load | 2011 |
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; HIV; HIV Infections; Humans; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyridazines; Pyrimidines; Viral Load; Young Adult | 2012 |
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopropanes; Desogestrel; Drug Interactions; Ethinyl Estradiol; Female; HIV; HIV Infections; Humans; Logistic Models; Middle Aged; Nevirapine; Progesterone; Prospective Studies; Thailand; Young Adult | 2013 |
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Nelfinavir; Oxazines; Random Allocation; RNA, Messenger; Stavudine; Treatment Failure | 2002 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure | 2003 |
Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cryptococcus neoformans; Cyclopropanes; Female; HIV; Humans; Male; Meningitis, Cryptococcal; Oxazines; RNA, Viral; Thailand; Time Factors | 2003 |
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cyclopropanes; Drug Therapy, Combination; Female; Glucagon; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Insulin Resistance; Lipids; Lipoproteins; Male; Nevirapine; Oxazines; Pilot Projects; RNA, Viral; Viral Load | 2004 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2006 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Costs and Cost Analysis; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Liver; Liver Diseases; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coculture Techniques; Cross-Sectional Studies; Cyclopropanes; Genotype; HIV; HIV Infections; Humans; In Situ Hybridization; Lymph Nodes; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Replication | 2000 |
Other Studies
82 other study(ies) available for efavirenz and HIV
| Article | Year |
|---|---|
Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives.
Topics: Cell Line; HIV; Humans; Isatin; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Models, Molecular; Reverse Transcriptase Inhibitors | 2005 |
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication | 2008 |
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; Drug Stability; HIV; HIV Reverse Transcriptase; Humans; Imidazoles; Indazoles; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfur Compounds | 2009 |
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Cell Survival; Cell Transformation, Viral; Computer Simulation; Crystallography, X-Ray; HIV; HIV Reverse Transcriptase; Humans; Microbial Sensitivity Tests; Models, Chemical; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship | 2009 |
Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
Topics: Anti-HIV Agents; Cell Line; HIV; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Iodopyridones; Mutation; Small Molecule Libraries | 2009 |
Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules.
Topics: Anti-HIV Agents; Enzyme Activation; Enzyme Stability; HIV; HIV Reverse Transcriptase; Models, Molecular; Molecular Structure; Protein Multimerization; Reverse Transcriptase Inhibitors; Small Molecule Libraries; Structure-Activity Relationship; Temperature; Virus Replication | 2016 |
Rational design, synthesis, anti-HIV-1 RT and antimicrobial activity of novel 3-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-1-(piperazin-1-yl)propan-1-one derivatives.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; Drug Design; Fungi; HIV; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2016 |
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Escherichia coli; HEK293 Cells; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thiophenes | 2016 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Indazoles; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2021 |
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Ethiopia; Female; Glucose; Glucose Metabolism Disorders; HIV; HIV Infections; Humans; Insulin; Male; Prevalence; Ritonavir | 2022 |
Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine.
Topics: Acquired Immunodeficiency Syndrome; HIV; HIV Infections; Humans; Precision Medicine; Reverse Transcriptase Inhibitors | 2023 |
Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; HIV; HIV Infections; Humans; Male; Viral Load | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis | 2023 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2020 |
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine | 2020 |
Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Arthralgia; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Erectile Dysfunction; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nausea; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Quality of Life; Registries; Sweden | 2020 |
Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors.
Topics: Adult; Alkynes; Anti-HIV Agents; Antidepressive Agents; Benzoxazines; Cyclopropanes; Depression; Drug Prescriptions; Female; HIV; HIV Infections; Humans; Incidence; Male; Observational Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Suicidal Ideation; Translational Research, Biomedical; United States | 2021 |
Population Approach to Efavirenz Therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2017 |
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Topics: Age Factors; Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Ethnicity; Female; Gene Frequency; Genotype; HIV; HIV Infections; Humans; Male; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sex Factors; Sweden; Viral Load | 2017 |
Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV; Microbial Sensitivity Tests; Molecular Conformation; Photolysis; Reverse Transcriptase Inhibitors; Solvents | 2017 |
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nervous System; Nevirapine; Ritonavir | 2018 |
Reply to Van de Wijer et al.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nevirapine; Ritonavir | 2018 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Treatment Outcome; Viral Load; Zidovudine | 2018 |
Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".
Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines | 2018 |
Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction.
Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines | 2018 |
A validated liquid chromatography/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients.
Topics: Alkynes; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Female; Hair; HIV; HIV Infections; Humans; Limit of Detection; Male; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry | 2018 |
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Depression; Female; Genotype; HIV; HIV Infections; Humans; Male; Odds Ratio; Polymorphism, Single Nucleotide; Prospective Studies; Uganda; Viral Load | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nevirapine; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tertiary Healthcare | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Would a CYP2B6 test help HIV patients being treated with efavirenz?
Topics: Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug-Related Side Effects and Adverse Reactions; Genotype; HIV; HIV Infections; Humans; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
Impact of pharmacogenetics on CNS side effects related to efavirenz.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers, Pharmacological; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide | 2013 |
Trials challenging HIV drug doses could usher in huge cost cuts.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Costs and Cost Analysis; Cyclopropanes; Dose-Response Relationship, Drug; HIV; HIV Infections; Humans | 2013 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Female; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics | 2014 |
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; South Africa; Treatment Failure; Viremia; Young Adult | 2014 |
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Validation of Computational Approaches for Antiretroviral Dose Optimization.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Dosage Calculations; Gene Expression; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Statistical; Mutation Rate | 2016 |
Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Plasma; Polymorphism, Genetic; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
First-line antiretroviral drug discontinuations in children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine | 2017 |
MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells.
Topics: Alkynes; Benzoxazines; Cell Line; Cyclopropanes; Dimerization; HIV; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Protein Binding; Protein Interaction Mapping; Protein Subunits; Reverse Transcriptase Inhibitors | 2008 |
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopropanes; Female; HIV; HIV Infections; Humans; Liver Function Tests; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tuberculosis, Pulmonary | 2009 |
Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naïve and experienced patients.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV; HIV Infections; Humans; Male; Molecular Diagnostic Techniques; Mutation, Missense; Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Viral Load | 2009 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2010 |
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Child; Cyclopropanes; Female; Flow Cytometry; Global Health; HIV; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Nevirapine; Policy; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Public Health | 2011 |
Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Humans; Male; Tuberculosis; Viral Load; Viremia | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials, Phase II as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; RNA, Viral; South Africa; Young Adult | 2011 |
Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Delivery Systems; Drug Synergism; Ethylenediamines; HIV; Humans; Micelles; Nanocapsules; Poloxamer; Solubility | 2011 |
Absence seizures associated with efavirenz initiation.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Epilepsy, Absence; Female; Genetic Predisposition to Disease; Genotype; HIV; HIV Infections; Homozygote; Humans; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; South Africa; Viral Load | 2011 |
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Hospitals, Public; Humans; Infant; Lopinavir; Male; Mycobacterium tuberculosis; Recurrence; Ritonavir; South Africa; Survival Analysis; Tuberculosis, Pulmonary; Viral Load | 2011 |
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation, Missense; Nevirapine; Nitriles; Prevalence; Pyridazines; Pyrimidines | 2011 |
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Topics: Alkynes; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Coinfection; Cryptococcus neoformans; Cyclopropanes; Half-Life; HIV; HIV Infections; Humans; Male; Meningitis, Cryptococcal; Middle Aged; Tandem Mass Spectrometry | 2012 |
Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Gene Expression Regulation, Viral; Genes, Reporter; Genes, Viral; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Luciferases; Macrophages; Microbial Sensitivity Tests; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Time Factors | 2012 |
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
Topics: Alkynes; Benzoxazines; Body Mass Index; Computer Simulation; Cyclopropanes; Drug Dosage Calculations; Drug Monitoring; HIV; HIV Infections; Humans; Male; Middle Aged; Obesity; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Viral Load | 2012 |
What do molecules do when we are not looking? State sequence analysis for stochastic chemical systems.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genome, Viral; HIV; Markov Chains; Mutation; Probability; Sodium Channels; Software; Stochastic Processes | 2012 |
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biotransformation; Catalysis; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV; HIV Infections; Humans; Microsomes, Liver; Oxazines; Oxidoreductases, N-Demethylating; Recombinant Proteins | 2003 |
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Forecasting; Guideline Adherence; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nevirapine; Oxazines; Treatment Failure; Viral Load | 2004 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delavirdine; DNA, Complementary; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Selection, Genetic; Viremia | 2004 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data.
Topics: Alkynes; Benzoxazines; Clone Cells; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; HIV; HIV Infections; Humans; Longitudinal Studies; Markov Chains; Models, Genetic; Oxazines; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA | 2007 |
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Genotype; HIV; HIV Infections; Humans; Lopinavir; Male; Oxazines; Oxidoreductases, N-Demethylating; Pyrimidinones | 2006 |
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 2006 |
Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays.
Topics: Alkynes; Benzoxazines; Blood Proteins; Cell Culture Techniques; Cyclopropanes; HIV; Humans; Immunoglobulin G; Leukocytes, Mononuclear; Oxazines; Protein Binding; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication | 2006 |
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load | 2007 |
Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.
Topics: Alkynes; Azepines; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Oxazines; Population Dynamics; Reverse Transcriptase Inhibitors; Time Factors; Urea; Viral Plaque Assay | 1997 |
[DuPont-Pharma Laboratories. Sustiva].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Brain; Cerebrospinal Fluid; Cyclopropanes; HIV; HIV Infections; Humans; Oxazines; RNA, Viral | 1998 |
Chemical process evolution of efavirenz, a potent non-nucleosidal HIV reverse transcriptase inhibitor.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV; Models, Molecular; Molecular Structure; Oxazines; Reverse Transcriptase Inhibitors; Stereoisomerism | 1999 |
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors; Uracil; Viral Load | 2000 |
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Phenotype; Ritonavir; Saquinavir; Treatment Failure | 2000 |
The tolerability of efavirenz after nevirapine-related adverse events.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2000 |
[Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Oxazines | 2001 |
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Efavirenz (Sustiva).
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Oxazines; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2000 |